Every article, presentation, spotlight, and news item we've tagged to Mental and Cognitive Health.
Showing 1–24 of 124
Modifiable risk factors drive both early-onset and late-onset dementia, with distinct profiles emerging between the two presentations. Identifying these factors creates measurable intervention points for primary prevention before cognitive decline becomes apparent.
Prolonged stress—distinct from acute stress—activates molecular pathways in yeast that recapitulate aging hallmarks including proteostasis collapse and epigenetic dysregulation. These changes are reversible upon stress relief, and the underlying genes are conserved across all life domains, suggesting aging may represent a maladaptive long-term stress response rather than passive damage accumulation.
Older adults exhibit measurable declines in everyday decision-making driven by sensory and cognitive changes, with environmental design and support structures demonstrating capacity to mitigate these effects. This directly impacts functional independence and quality of life across the lifespan.
Mendelian randomization analysis of drug targets reveals limited repurposing opportunities for vascular dementia prevention. Beta-blockers targeting ADRB1 showed potential benefit, while ACE inhibitors demonstrated a possible risk signal, suggesting current cardiovascular drug strategies may not directly translate to dementia prevention.
Lifetime cognitive enrichment from childhood through late life is associated with a 38% reduced dementia risk and delays cognitive decline by 5–7 years. The protective effect accumulates across all life stages, with late-life engagement showing the strongest individual contribution to risk reduction.
Repeated measures of physical activity in community-dwelling older adults reveal that the protective association with dementia risk varies depending on timing relative to diagnosis, suggesting that activity patterns in the years immediately preceding cognitive decline may be more predictive than earlier lifetime activity. This finding reframes physical activity from a static risk factor into a dynamic variable whose relevance to dementia prevention depends on proximity to disease onset.
Subjective cognitive decline in older adults correlates with reduced capacity for instrumental daily activities, prior falls, and depressive symptoms. This association suggests that perceived cognitive changes may reflect broader functional and neurological stress rather than isolated memory loss.
The Neuroscience of Vitality and Aging Conference brings together researchers, clinicians, policymakers, and investors to address brain health preservation and neurodegenerative disease prevention. The event recognizes brain aging as a modifiable biological process and aims to translate fragmented research across academia, industry, and policy into coordinated clinical advancement.
Burnout among direct care workers in Chinese long-term care facilities correlates with job demands, resource availability, and individual stress responses. Understanding these multilevel factors is critical for sustaining the quality of care delivered to aging populations and protecting workforce stability in geriatric settings.
Alzheon has dosed the first healthy volunteers in a Phase 1 trial of ALZ-507, an oral Alzheimer's candidate designed to prevent amyloid clumping and correct APOE4 dysfunction. The drug represents a shift toward earlier intervention and simplified delivery in a disease where accessibility and tolerability have historically limited treatment adoption.
Uncorrected cataracts appear associated with elevated dementia risk, and cataract surgery may reduce that risk. This relationship suggests that preserving visual input and the neural processing it supports plays a measurable role in cognitive preservation.
A $6.2 million NIH grant funds AI-driven analysis of 1,800 Alzheimer's-linked genes to identify genetic targets upstream of amyloid pathology, shifting focus from symptomatic treatment to early-stage vulnerability. Current amyloid-targeting drugs slow progression at best; identifying genetic determinants of susceptibility may enable earlier, more precise intervention before neurodegeneration becomes symptomatic.
A large genetic study finds that lifelong reductions in atherogenic lipoproteins are associated with lower dementia risk, contradicting the concern that cholesterol-lowering strategies harm cognitive function. This evidence clarifies a persistent misconception in longevity planning.
Brain imaging from 33,573 participants reveals that accelerated brain aging mediates the relationship between cardiac structural changes and mental health disorders. Smoking and physical inactivity emerge as modifiable factors that influence this heart-brain-disorder pathway, suggesting intervention points in the progression toward age-related cognitive and psychiatric decline.
Cognitive strategy interventions implemented through participatory action research enable people with neurocognitive disorders to maintain engagement in meaningful activities and preserve dignity. The approach leverages procedural memory—the capacity to retain learned motor and behavioral patterns—as a foundation for functional preservation despite cognitive decline.
Alzheon has initiated Phase 1 trials of ALZ-507, an oral small molecule designed to inhibit neurotoxic amyloid oligomer formation and correct APOE4 dysfunction. The compound demonstrates favorable preclinical safety and pharmacokinetic profiles supporting once-daily dosing, with Phase 2 studies planned across Alzheimer's disease, Down syndrome-associated AD, and cerebral amyloid angiopathy.
Mild cognitive impairment (MCI) cases substantially reduce the predictive accuracy of Alzheimer's disease diagnostic models built on routine clinical variables. This finding challenges the assumption that standard biomarkers and clinical assessments alone can reliably stratify progression risk in early cognitive decline.
Older adults and individuals with cognitive impairment from lower socioeconomic backgrounds remain significantly underrepresented in dementia research, limiting the generalizability of findings and slowing therapeutic development for populations at highest risk. Addressing barriers to research participation directly affects whether treatments will be validated in the populations that need them most.
Chronic pursuit of peak performance without adequate recovery locks the nervous system in a prolonged stress state, diverting resources from sleep, digestion, immunity, and cognitive function. This pattern drives burnout and disease rather than sustainable health, requiring deliberate recovery practices and calendar curation as foundational interventions.
A 20-year follow-up of the ACTIVE trial found that speed-of-processing training with booster sessions reduced dementia diagnoses in older adults, a rare signal of efficacy in prevention research anchored to clinical diagnoses rather than cognitive test scores alone.
Visual impairment in older adults—both distance and near vision—correlates with measurable cognitive decline independent of age and education. The association suggests vision loss creates a bidirectional relationship with cognitive performance, making visual function a potentially modifiable risk factor in cognitive aging.
Levetiracetam, an FDA-approved epilepsy drug, blocks production of amyloid-beta 42 by subtly altering protein trafficking within neurons—intervening decades before Alzheimer's symptoms emerge. This represents a shift from clearing existing plaques to preventing their formation at the source.
Chronic acid accumulation from aging and stress depletes the body's buffering capacity, disrupting communication between physiological systems and driving frailty through impaired energy metabolism. This acid-base dysregulation mechanism unifies existing frailty models and identifies diet, exercise, and buffering strategies as therapeutic targets.
Type 2 diabetes with worsening diabetic retinopathy correlates with significantly elevated dementia risk, with severe eye disease conferring 58% higher risk for any dementia and more than double the risk for vascular dementia. The retina serves as a measurable window into microvascular integrity throughout the body, including the cerebral vasculature, making routine eye screening a potential early intervention point for cognitive decline.
